Axogen Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.21 (market cap $78.85B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 30.2× Axogen Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | MDLZ | |
|---|---|---|
Market Cap | $2.61B | $78.85B |
Sector | Technology | Consumer Staples |
52-Week High | $48.48 | $64.99 |
52-Week Low | $14.16 | $51.51 |
Enterprise Value | $2.52B | $99.19B |
Dividend Yield | — | 3.24% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
MDLZ trades at $61.99, up 0.75% today, with a bullish technical signal from moving averages and support at $61. The company reported Q2 2026 EPS of $0.73, beating estimates, and raised its organic sales outlook. Revenue grew to $38.54B in 2025, though net income margin declined to 6.36%. Analyst consensus is strongly bullish with a $70.50 price target.
Outlook is positive due to earnings beats and emerging market growth, but risks include margin pressure and high P/E of 37.75. Institutional activity is mixed, with some firms increasing stakes while others reduced holdings. The stock offers upside to target but faces execution risks in a competitive consumer staples sector.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →